MindMaze Therapeutics Holding SA (MMTXZ.XC)
Cboe UK · CHF · Healthcare · Biotechnology
CHF 0.1602 (+0.00%) as of
Key statistics
- Market cap
- 24.45M
- EPS (TTM)
- -0.2500
- Dividend yield
- 0.00%
- 52-week range
- 0.1342 – 2.8150
- Revenue (TTM)
- 1.2M
- Profit margin
- 0.00%
- Volume
- 13.24k
About MindMaze Therapeutics Holding SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Geneva, Switzerland
- Employees
- 10
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.